Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Serevent
Generic Name
Salmeterol Xinafoate
Active Ingredient
Salmeterol XinafoateCategory
Other
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 50 ug/1 | POWDER, METERED | ORAL, RESPIRATORY (INHALATION) | 0173-0521 |
Detailed information about Serevent
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Serevent, you must consult a qualified healthcare professional.
Salmeterol Xinafoate is a long-acting beta2-adrenergic agonist (LABA) used for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing bronchial smooth muscle to improve airflow and reduce symptoms.
For the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD), the standard adult dosage of Salmeterol Xinafoate is one inhalation (50 mcg) twice daily, approximately 12 hours apart (morning and evening). This dosage is consistent across both the DPI (Diskus) and MDI formats, though the number of puffs may vary depending on the specific product's concentration.
For the prevention of Exercise-Induced Bronchospasm (EIB), the recommended dose is one inhalation (50 mcg) at least 30 to 60 minutes before exercise. It is crucial to note that if a patient is already taking Salmeterol Xinafoate twice daily for asthma or COPD maintenance, they should not take an additional dose for EIB prevention. Taking more than the prescribed dose (100 mcg daily) significantly increases the risk of cardiovascular side effects and does not provide additional clinical benefit.
Salmeterol Xinafoate is approved for use in children aged 4 years and older for the maintenance treatment of asthma and the prevention of EIB. The dosage is the same as the adult dose: one inhalation (50 mcg) twice daily for maintenance or one inhalation 30 minutes before exercise for EIB.
Safety and effectiveness in children under 4 years of age have not been established. Pediatric patients should always be supervised by an adult when using the inhaler to ensure proper technique and full delivery of the dose. Healthcare providers emphasize that in children with asthma, salmeterol must never be used without a concurrent inhaled corticosteroid.
No formal studies have been conducted in patients with renal (kidney) impairment. However, since only a small fraction of the dose is excreted renally, dosage adjustments are generally not considered necessary for patients with kidney disease. Healthcare providers will still monitor these patients for any signs of systemic toxicity.
Because salmeterol is primarily metabolized by the liver (specifically the CYP3A4 enzyme), patients with hepatic (liver) impairment may experience increased systemic concentrations of the drug. While there are no specific guidelines for dose reduction, these patients should be monitored closely for cardiovascular side effects, such as increased heart rate or tremors.
Clinical trials have shown that the safety and efficacy of Salmeterol Xinafoate in patients aged 65 and older are similar to those in younger adults. No specific dosage adjustment is required for the elderly, although caution is advised due to the higher prevalence of underlying cardiovascular conditions in this population.
Proper administration is critical for the efficacy of Salmeterol Xinafoate.
If you miss a dose of Salmeterol Xinafoate, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at once to make up for a missed one. Maintaining a consistent 12-hour interval helps keep the airways open throughout the day and night.
Signs of a Salmeterol Xinafoate overdose include an abnormally fast heart rate (tachycardia), tremors, palpitations, chest pain, headache, and a feeling of nervousness. Severe overdose can lead to hypokalemia (low potassium levels) and cardiac arrhythmias. In case of a suspected overdose, seek emergency medical attention immediately or contact a poison control center. Treatment usually involves supportive care and monitoring of cardiac function and serum potassium levels.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, even if you feel better.
Common side effects of Salmeterol Xinafoate are often related to its action as a beta-adrenergic stimulant. These effects are usually mild and may diminish as the body adjusts to the medication.
> Warning: Stop taking Salmeterol Xinafoate and call your doctor immediately if you experience any of these.
Prolonged use of LABAs like Salmeterol Xinafoate can lead to a phenomenon known as 'beta-receptor downregulation' or tolerance. This means that over time, the receptors may become less responsive to the drug. This is why it is critical to always use salmeterol in combination with an inhaled corticosteroid (ICS) for asthma, as the ICS helps prevent this downregulation and treats the underlying inflammation. There is no evidence that long-term use of salmeterol at recommended doses causes permanent organ damage, provided it is used as part of a comprehensive management plan.
Historically, the FDA issued a Boxed Warning for all LABAs, including Salmeterol Xinafoate, due to data from the SMART (Salmeterol Multicenter Asthma Research Trial) study, which suggested an increased risk of asthma-related death when LABAs were used as monotherapy (without an ICS).
Current Status: In 2017, the FDA removed the Boxed Warning for LABAs when used in a fixed-dose combination with an ICS, based on large-scale safety trials (AUSTRI and VESTRI) which showed that the combination does not significantly increase the risk of serious asthma-related events compared to ICS alone. However, the warning remains that Salmeterol Xinafoate should NEVER be used alone for the treatment of asthma. It must always be used with an inhaled corticosteroid. For COPD patients, the risk profile is different, and salmeterol may be used without an ICS if determined appropriate by a healthcare provider.
Report any unusual symptoms to your healthcare provider. Monitoring your response to the medication is an essential part of long-term respiratory care.
Salmeterol Xinafoate is a maintenance medication and should not be used to treat acute symptoms of asthma or COPD. Patients must always have a fast-acting rescue inhaler (such as albuterol) available for sudden attacks. If your rescue inhaler is not working as well as it used to, or if you need to use it more than twice a week (for asthma), you must contact your healthcare provider immediately, as this indicates your condition is not well-controlled.
While the FDA has modified the Boxed Warning for combination products, the fundamental safety principle for Salmeterol Xinafoate remains: In the treatment of asthma, Salmeterol Xinafoate must only be used as additional therapy for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. It should not be used in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids. Monotherapy with a LABA in asthma is contraindicated because it increases the risk of asthma-related death.
Healthcare providers will typically perform the following monitoring for patients on Salmeterol Xinafoate:
Salmeterol Xinafoate generally does not interfere with the ability to drive or operate machinery. However, if you experience side effects like tremors or dizziness, you should wait until these symptoms subside before engaging in tasks that require precision or focus.
There are no direct pharmacological interactions between Salmeterol Xinafoate and alcohol. However, excessive alcohol consumption can sometimes trigger asthma symptoms or interact with other medications you may be taking. It is best to discuss your alcohol intake with your doctor.
Do not stop taking Salmeterol Xinafoate abruptly. Stopping maintenance therapy can lead to a rapid worsening of your respiratory symptoms. If your doctor decides to discontinue the medication, they will usually do so by ensuring you are still covered by an inhaled corticosteroid or by transitioning you to a different maintenance agent. There is no 'withdrawal syndrome' in the traditional sense, but the return of airway inflammation and bronchoconstriction can be severe.
> Important: Discuss all your medical conditions, including heart problems, high blood pressure, seizures, or thyroid issues, with your healthcare provider before starting Salmeterol Xinafoate.
Salmeterol Xinafoate does not typically interfere with standard laboratory tests. However, it can cause transient decreases in serum potassium and increases in blood glucose, which may be reflected in metabolic panels. If you are undergoing a cardiac stress test, ensure the technician knows you are using a LABA, as it may affect heart rate response.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines which often contain stimulants.
Salmeterol Xinafoate is strictly contraindicated in the following scenarios:
In these conditions, the risks and benefits must be carefully weighed by a healthcare provider:
Patients who have experienced severe side effects or allergic reactions to other long-acting beta-agonists (such as formoterol, vilanterol, or indacaterol) may also react to salmeterol. While they are chemically distinct, their shared mechanism of action at the beta2-receptor means that systemic side effects (like tachycardia) will likely be similar across the class.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of cardiac issues or allergies, before prescribing Salmeterol Xinafoate.
Salmeterol Xinafoate is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies of salmeterol in pregnant women. Animal studies have shown some evidence of fetal risk (at very high systemic doses), including ossification of the sternebrae and cranial bones.
In clinical practice, the GINA (Global Initiative for Asthma) guidelines suggest that maintaining good asthma control is paramount for the health of both the mother and the fetus. Poorly controlled asthma increases the risk of preeclampsia, low birth weight, and preterm delivery. Therefore, if Salmeterol Xinafoate is necessary for asthma control, it is generally continued during pregnancy, usually in combination with an ICS. Use during labor and delivery is generally avoided unless necessary, as beta-agonists can interfere with uterine contractility.
It is not known whether salmeterol is excreted in human milk. However, because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from salmeterol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Given the very low systemic concentrations of salmeterol after inhalation, the amount an infant would receive through breast milk is likely to be extremely small.
Salmeterol Xinafoate is FDA-approved for use in children 4 years of age and older. The safety and efficacy in children under 4 have not been established. In pediatric patients, it is vital to ensure the child can master the inhalation technique. For children with asthma, the 'LABA only' contraindication is strictly enforced; they must always use an ICS. Studies have shown that salmeterol does not appear to affect the growth rate of children, unlike some systemic corticosteroids, though the inhaled corticosteroid used alongside it should be monitored for growth effects.
Clinical studies of Salmeterol Xinafoate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are more likely to have underlying cardiovascular disease, such as hypertension or arrhythmias, which can be exacerbated by beta-agonists. Additionally, age-related declines in hepatic function may theoretically lead to higher systemic levels, though this is rarely clinically significant for the inhaled route. Caution and regular monitoring of heart rate and blood pressure are recommended.
The pharmacokinetics of salmeterol have not been studied in patients with renal impairment. However, since less than 25% of the drug is excreted in the urine, renal failure is not expected to significantly alter the clearance of the drug. No dosage adjustment is typically required, though patients should be monitored for systemic effects.
Salmeterol is primarily cleared by hepatic metabolism (CYP3A4). In patients with significant hepatic impairment (Child-Pugh Class B or C), systemic accumulation of the drug may occur. This increases the risk of beta-mediated side effects like tachycardia and tremors. While there are no specific dose-adjustment tables, healthcare providers may choose to monitor these patients more frequently or use alternative therapies if systemic toxicity becomes an issue.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Salmeterol Xinafoate is a long-acting beta2-adrenergic agonist (LABA). Its primary molecular mechanism involves binding to beta2-receptors in the smooth muscle of the airways. This binding activates the Gs-protein-adenylyl cyclase-cAMP pathway. The resulting increase in intracellular cyclic AMP (cAMP) activates protein kinase A (PKA), which in turn phosphorylates several proteins involved in muscle contraction. This leads to a decrease in intracellular calcium and the inhibition of myosin light-chain kinase, resulting in the relaxation of the bronchial smooth muscle and bronchodilation.
What sets salmeterol apart is its 'exosite' binding. The molecule has a long lipophilic tail that anchors it to a specific site on the receptor protein, allowing the active head of the molecule to swing in and out of the receptor's active site. This 'tethered' binding explains why its effect lasts for 12 hours, compared to the 4-6 hours of short-acting agonists like albuterol.
The pharmacodynamic effect of Salmeterol Xinafoate is characterized by a relatively slow onset (10–20 minutes) compared to SABAs, with peak bronchodilation occurring between 3 and 4 hours after inhalation. The duration of effect is consistently 12 hours. Unlike SABAs, repeated dosing of salmeterol does not typically lead to significant accumulation of effect, but it does provide a stable baseline of airway caliber. It also inhibits the late-phase response to allergens and reduces bronchial hyperresponsiveness, though it does not possess significant anti-inflammatory properties.
| Parameter | Value |
|---|---|
| Bioavailability | Low (systemic levels often undetectable) |
| Protein Binding | ~96% |
| Half-life | ~5.5 hours (terminal) |
| Tmax | 5 to 20 minutes (plasma) |
| Metabolism | Hepatic (primarily CYP3A4) |
| Excretion | Fecal (~60%), Renal (~25%) |
Salmeterol Xinafoate is classified as a Long-Acting Beta2-Adrenergic Agonist (LABA). It is grouped with other medications such as formoterol, vilanterol, and indacaterol. Within the broader therapeutic area of respiratory medicine, it is considered a 'maintenance bronchodilator,' distinct from 'rescue bronchodilators' (SABAs) and 'anti-inflammatory controllers' (Inhaled Corticosteroids).
Common questions about Serevent
Salmeterol Xinafoate is primarily used for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by keeping the airways open for 12 hours, which helps prevent symptoms like wheezing, shortness of breath, and chest tightness. In asthma patients, it must always be used alongside an inhaled corticosteroid to address underlying inflammation. It is also approved for the prevention of exercise-induced bronchospasm (EIB) when taken 30 minutes before physical activity. It is important to remember that this medication is not a rescue inhaler and should not be used to treat a sudden asthma attack.
The most common side effects reported by patients using Salmeterol Xinafoate include headaches, tremors (especially in the hands), and a racing or pounding heart (palpitations). Some people may also experience throat irritation, a dry mouth, or a cough immediately after using the inhaler. These symptoms are generally mild and are caused by the drug's stimulation of beta-receptors throughout the body. Most of these side effects tend to decrease as your body becomes accustomed to the medication. However, if these symptoms become severe or persistent, you should consult your healthcare provider for a dosage review.
There is no known direct interaction between alcohol and Salmeterol Xinafoate that would make it dangerous to consume in moderation. However, alcohol can sometimes act as a trigger for asthma symptoms in certain individuals or may interact with other medications you are taking for your respiratory condition. Excessive alcohol consumption can also lead to dehydration, which may make respiratory secretions thicker and harder to clear. It is always best to discuss your lifestyle habits with your doctor to ensure that alcohol consumption does not interfere with your overall treatment plan for asthma or COPD.
Salmeterol Xinafoate is generally used during pregnancy only if the potential benefit justifies the potential risk to the fetus. While animal studies have shown some risks at very high doses, there is no conclusive evidence of harm in humans at standard inhaled doses. Most medical guidelines, including those from the Global Initiative for Asthma (GINA), emphasize that maintaining stable asthma control is critical for a healthy pregnancy, as uncontrolled asthma poses a greater risk to the baby. Your doctor will likely recommend continuing the medication if it is necessary to keep your breathing stable. Always inform your obstetrician and pulmonologist if you are pregnant or planning to conceive.
Salmeterol Xinafoate is a long-acting medication and does not provide immediate relief. After inhalation, it typically takes about 10 to 20 minutes to begin working, with the full bronchodilatory effect peaking between 3 and 4 hours. Because of this relatively slow onset, it is never used for the emergency treatment of sudden shortness of breath. Its primary advantage is its duration; once it reaches its full effect, it continues to keep the airways dilated for at least 12 hours. This makes it ideal for preventing nighttime symptoms and providing all-day coverage when taken twice daily.
You should not stop taking Salmeterol Xinafoate suddenly without first consulting your healthcare provider. Because it is a maintenance medication, stopping it can cause your asthma or COPD symptoms to return or worsen significantly within a few days. If your doctor decides that you no longer need the medication, they will typically guide you on how to transition to a different treatment or monitor your lung function closely during the change. Abruptly stopping the drug does not cause a chemical withdrawal, but the loss of airway protection can lead to a dangerous increase in bronchial constriction and inflammation.
If you miss a dose of Salmeterol Xinafoate, you should skip the missed dose and take your next regularly scheduled dose at the normal time. Do not attempt to 'double up' or take two doses at once to compensate for the one you missed, as this can increase the risk of cardiovascular side effects like a rapid heart rate or high blood pressure. Try to maintain a consistent schedule of taking the medication every 12 hours (for example, at 8 AM and 8 PM). Using a reminder app or keeping your inhaler near your toothbrush can help you stay consistent with your maintenance routine.
Weight gain is not a recognized or common side effect of Salmeterol Xinafoate. Unlike oral corticosteroids (such as prednisone), which are known to cause weight gain and fluid retention when used long-term, salmeterol is a bronchodilator that acts locally in the lungs with very little systemic absorption. If you notice unexpected weight gain while taking this medication, it is more likely related to other factors, such as a decrease in physical activity due to respiratory symptoms or the side effects of other medications like oral steroids. You should discuss any significant changes in weight with your healthcare provider to identify the underlying cause.
Salmeterol Xinafoate can be taken with many other medications, but there are several important exceptions. It should not be used with non-selective beta-blockers (like propranolol), as they can cause the airways to narrow. You should also be cautious when taking it with strong CYP3A4 inhibitors (like certain antifungals or HIV medications), as these can increase the amount of salmeterol in your blood and lead to heart-related side effects. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use to ensure there are no dangerous interactions.
Yes, Salmeterol Xinafoate is available as a generic medication. In the United States and other regions, generic versions of the Serevent Diskus have been approved by regulatory agencies like the FDA. These generic versions are required to demonstrate 'bioequivalence' to the brand-name drug, meaning they deliver the same amount of medication to the lungs and work in the same way. Choosing a generic version can often be a more cost-effective option for long-term maintenance therapy. However, you should ensure that the specific inhaler device (DPI vs. MDI) is one you are comfortable using, as the technique may vary slightly between manufacturers.